SCHEMBL1284641

SCHEMBL1284641

CC(C)C(=O)NNc1ccc(F)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR2 O15552 1/20 0.49
ALDH1A1 P00352 8/20 0.46
RAB9A P51151 7/20 0.46
GAA P10253 2/20 0.45
NPC1 O15118 6/20 0.41
TP53 P04637 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
ABL1 P00519 1/20 0.41
KDM4E B2RXH2 3/20 0.40
CYP2C19 P33261 2/20 0.39
GRM5 P41594 2/20 0.39
LMNA P02545 1/20 0.39
ALOX15 P16050 1/20 0.39
POLB P06746 1/20 0.39
HTT P42858 1/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
KMT2A Q03164 1/20 0.39
CXCR2 P25025 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20579046 0.85 FFAR2 (0.45) FFAR2ALDH1A1RAB9AGAANPC1
SCHEMBL20579244 0.85 FFAR2 (0.45) FFAR2ALDH1A1RAB9AGAANPC1
SCHEMBL20579048 0.85 FFAR2 (0.45) FFAR2ALDH1A1RAB9AGAANPC1
SCHEMBL20579241 0.85 FFAR2 (0.45) FFAR2ALDH1A1RAB9AGAANPC1
SCHEMBL19699480 0.83 FFAR2 (0.62) FFAR2ALDH1A1RAB9ANPC1TP53
SCHEMBL20579176 0.83 FFAR2 (0.43) FFAR2ALDH1A1RAB9AGAANPC1
SCHEMBL19054123 0.83 FFAR2 (0.49) FFAR2ALDH1A1RAB9AGAANPC1
SCHEMBL19022428 0.83 FFAR2 (0.49) FFAR2ALDH1A1RAB9AGAANPC1
SCHEMBL15008761 0.81 MAPT (0.47) FFAR2ALDH1A1RAB9AGAANPC1
SCHEMBL4074315 0.81 FDPS (0.46) RAB9AGAANPC1TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2788345-B1 DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT CHIESI FARM SPA (IT) 2020-06-10 EP disclosed
EP-2788345-B1 DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT CHIESI FARM SPA (IT) 2020-06-10 EP disclosed
EP-3004087-B1 DERIVATIVES OF [1,2,4]TRIAZOLO[4,3-A]PYRIDINE AS P38-MAP KINASE INHIBITORS CHIESI FARM SPA (IT) 2017-08-09 EP disclosed
EP-3004087-B1 DERIVATIVES OF [1,2,4]TRIAZOLO[4,3-A]PYRIDINE AS P38-MAP KINASE INHIBITORS CHIESI FARM SPA (IT) 2017-08-09 EP disclosed
US-9573949-B2 Derivatives of [1, 2, 4] triazolo [4, 3-a] pyridine as P38—MAP kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2017-02-21 US disclosed
US-9573949-B2 Derivatives of [1, 2, 4] triazolo [4, 3-a] pyridine as P38—MAP kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2017-02-21 US disclosed
EP-2788348-B1 KINASE INHIBITORS CHIESI FARMA SPA (IT) 2016-10-19 EP disclosed
EP-2788348-B1 KINASE INHIBITORS CHIESI FARMA SPA (IT) 2016-10-19 EP disclosed
US-9458154-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-10-04 US disclosed
US-9458154-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-10-04 US disclosed
US-8557797-B2 Triazolopyridine derivatives and their therapeutic use CHIESI FARMACEUTICI S.P.A. (IT) 2013-10-15 US disclosed
WO-2013083206-A1 DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT CHIESI FARMACEUTICI S.P.A. (IT) 2013-06-13 WO disclosed
WO-2013083606-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2013-06-13 WO disclosed
US-20130150361-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2013-06-13 US disclosed
US-20130150361-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2013-06-13 US disclosed
US-20130143914-A1 UREA DERIVATIVES AND THEIR THERAPEUTIC USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT CHIESI FARMACEUTICI S.P.A. (IT) 2013-06-06 US disclosed
US-20130143914-A1 UREA DERIVATIVES AND THEIR THERAPEUTIC USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT CHIESI FARMACEUTICI S.P.A. (IT) 2013-06-06 US disclosed
US-20120088763-A1 TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE CHIESI FARMACEUTICI S.P.A. (IT) 2012-04-12 US disclosed
US-20120088763-A1 TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE CHIESI FARMACEUTICI S.P.A. (IT) 2012-04-12 US disclosed
WO-2010094956-A1 TRIAZOLOPYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED. (GB) 2010-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143914-A1 UREA DERIVATIVES AND THEIR THERAPEUTIC USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT ARG2, MAPK1, URB2 FFAR2 2621/4885ALDH1A1 771/4885RAB9A 1255/4885
US-20120088763-A1 TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE CNKSR1, MOK, MAPK1 FFAR2 2360/4885ALDH1A1 1860/4885RAB9A 1762/4885
US-20130150361-A1 KINASE INHIBITORS MAPK1, MAP3K1, MAPK6 FFAR2 1692/4885ALDH1A1 1534/4885RAB9A 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.